Galectin Therapeutics (GALT) Earnings Analysis
Galectin Therapeutics (GALT) next reports earnings on 2026-08-13, consensus EPS -0.09 USD. Last quarter (2026-05-15) it missed with EPS -0.08 USD vs -0.06 USD est (-33.3%). It has beaten estimates in 4/7 recent quarters (57%). Trailing P/E -8.60.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does GALT next report earnings?
| Next earnings date | 2026-08-13 |
|---|---|
| Consensus EPS estimate | -0.09 USD |
| Revenue estimate | n/a |
GALT earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-15 | -0.08 USD | -0.06 USD | -33.3% | Miss |
| 2026-03-31 | -0.08 USD | -0.1 USD | +20% | Beat |
| 2025-11-14 | -0.13 USD | -0.11 USD | -18.2% | Miss |
| 2025-08-14 | -0.12 USD | -0.16 USD | +25% | Beat |
| 2025-05-15 | -0.15 USD | -0.2 USD | +25% | Beat |
| 2025-03-31 | -0.19 USD | -0.16 USD | -18.8% | Miss |
| 2024-11-14 | -0.18 USD | -0.2 USD | +10% | Beat |
Beat rate: 4/7 (57%) over reported quarters with consensus data.
GALT valuation and analyst view
| Trailing P/E | -8.60 |
|---|---|
| Trailing EPS | -0.39906 USD |
| Price / book | -1.77 |
| Dividend yield | 0.00% |
| Market cap | 0.24B |
| Analyst consensus | Buy (9 buy / 2 hold / 0 sell) |
| Avg price target | 11 USD |
Related research pages
Frequently asked questions
When is Galectin Therapeutics (GALT)'s next earnings date?
Galectin Therapeutics is next scheduled to report on 2026-08-13, with a consensus EPS estimate of -0.09 USD.
Did GALT beat earnings last quarter?
In its 2026-05-15 report, GALT posted EPS of -0.08 USD versus a -0.06 USD estimate — a miss of 33.3%.
What is GALT's earnings track record?
Over the last 7 reported quarters with consensus data, GALT beat estimates 4 times (57%).
What is GALT's current P/E ratio and EPS?
GALT trades at a trailing P/E of -8.60 on trailing EPS of -0.3990605332765802 USD.
What do analysts rate GALT?
Analyst consensus is "Buy" across 11 ratings (0 strong buy, 9 buy, 2 hold, 0 sell, 0 strong sell). Average 12-month price target: 11 USD.